Abstract
Gaucher disease is an autosomal recessive lysosomal storage disorder, caused by mutations in the GBA gene. The frequency of Gaucher disease patients and heterozygote carriers that developed Parkinson disease has been found to be above that of the control population. This fact suggests that mutations in the GBA gene can be involved in Parkison’s etiology. Analysis of large cohorts of patients with Parkinson disease has shown that there are significantly more cases bearing GBA mutations than those found among healthy individuals. Functional studies have proven an interaction between α-synuclein and GBA, the levels of which presented an inverse correlation. Mutant GBA proteins cause increases in α-synuclein levels, while an inhibition of GBA by α-synuclein has been also demonstrated. Saposin C, a coactivator of GBA, has been shown to protect GBA from this inhibition. Among the GBA variants associated with Parkinson disease, E326K seems to be one of the most prevalent. Interestingly, it is involved in Gaucher disease only when it forms part of a double-mutant allele, usually with the L444P mutation. Structural analyses have revealed that both residues (E326 and L444) interact with Saposin C and, probably, also with α-synuclein. This could explain the antagonistic role of these two proteins in relation to GBA.
Keywords: Gaucher disease, Parkinson disease, GBA mutations, E326K, L444P, saposin C, α-synuclein.
Current Protein & Peptide Science
Title:Involvement of Gaucher Disease Mutations in Parkinson Disease
Volume: 18 Issue: 7
Author(s): Lluisa Vilageliu and Daniel Grinberg*
Affiliation:
- Departament de Genetica, Facultat de Biología, Universitat de Barcelona, Av. Diagonal 643, E-08028 Barcelona,Spain
Keywords: Gaucher disease, Parkinson disease, GBA mutations, E326K, L444P, saposin C, α-synuclein.
Abstract: Gaucher disease is an autosomal recessive lysosomal storage disorder, caused by mutations in the GBA gene. The frequency of Gaucher disease patients and heterozygote carriers that developed Parkinson disease has been found to be above that of the control population. This fact suggests that mutations in the GBA gene can be involved in Parkison’s etiology. Analysis of large cohorts of patients with Parkinson disease has shown that there are significantly more cases bearing GBA mutations than those found among healthy individuals. Functional studies have proven an interaction between α-synuclein and GBA, the levels of which presented an inverse correlation. Mutant GBA proteins cause increases in α-synuclein levels, while an inhibition of GBA by α-synuclein has been also demonstrated. Saposin C, a coactivator of GBA, has been shown to protect GBA from this inhibition. Among the GBA variants associated with Parkinson disease, E326K seems to be one of the most prevalent. Interestingly, it is involved in Gaucher disease only when it forms part of a double-mutant allele, usually with the L444P mutation. Structural analyses have revealed that both residues (E326 and L444) interact with Saposin C and, probably, also with α-synuclein. This could explain the antagonistic role of these two proteins in relation to GBA.
Export Options
About this article
Cite this article as:
Vilageliu Lluisa and Grinberg Daniel*, Involvement of Gaucher Disease Mutations in Parkinson Disease, Current Protein & Peptide Science 2017; 18 (7) . https://dx.doi.org/10.2174/1389203717666160311115956
DOI https://dx.doi.org/10.2174/1389203717666160311115956 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein/protein and RNA/protein interactions are essential for molecular regulations
Protein-protein and RNA-protein interactions are fundamental to the intricate regulatory mechanisms that govern various cellular processes, playing a crucial role in maintaining the delicate balance and coordination within the complex molecular landscape. Proteins, the workhorses of the cell, engage in a myriad of interactions, both with other proteins and with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology The Clock Drawing Test: A Reasonable Instrument to Assess Probable Dementia in Primary Care?
Current Alzheimer Research Alzheimer's Disease-Like Pathologies and Cognitive Impairments Induced by Formaldehyde in Non-Human Primates
Current Alzheimer Research Persistent Hiccups as an Atypical Initial Presentation of COVID-19: A Case Report
Infectious Disorders - Drug Targets Acute Management in Very Old Patients: Is Thrombolysis Safe?
Cardiovascular & Hematological Disorders-Drug Targets The Clinical and Biological Relationship between Type II Diabetes Mellitus and Alzheimers Disease
Current Alzheimer Research Inhibition of β-Amyloid Aggregation by Albiflorin, Aloeemodin and Neohesperidin and their Neuroprotective Effect on Primary Hippocampal Cells Against β-Amyloid Induced Toxicity
Current Alzheimer Research Intracellular Accumulation of Toxic Turn Amyloid-β is Associated with Endoplasmic Reticulum Stress in Alzheimer’s Disease
Current Alzheimer Research The Links between Cardiovascular Diseases and Alzheimer's Disease
Current Neuropharmacology Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects
Current Alzheimer Research Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Low 25OH Vitamin D2 Levels Found in Untreated Alzheimer’s Patients, Compared to Acetylcholinesterase-Inhibitor Treated and Controls
Current Alzheimer Research The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Characterization of Intrinsically Disordered Proteins in Healthy and Diseased States by Nuclear Magnetic Resonance
Reviews on Recent Clinical Trials Melatonin and Its Therapeutic Potential in Neuroprotection
Central Nervous System Agents in Medicinal Chemistry Conference Report: Nanotechnology Congress & Expo 2015, Frankfurt, Germany August 11-13, 2015
CNS & Neurological Disorders - Drug Targets Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology